These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21640708)

  • 1. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.
    Kim SY; Kang JJ; Lee HH; Kang JJ; Kim B; Kim CG; Park TK; Kang H
    Biochem Biophys Res Commun; 2011 Jul; 410(2):224-8. PubMed ID: 21640708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
    Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
    J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Kiyoi H; Ohno R; Ueda R; Saito H; Naoe T
    Oncogene; 2002 Apr; 21(16):2555-63. PubMed ID: 11971190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
    Beghini A; Cairoli R; Morra E; Larizza L
    Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
    Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
    Rubin BP; Singer S; Tsao C; Duensing A; Lux ML; Ruiz R; Hibbard MK; Chen CJ; Xiao S; Tuveson DA; Demetri GD; Fletcher CD; Fletcher JA
    Cancer Res; 2001 Nov; 61(22):8118-21. PubMed ID: 11719439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
    Masson K; Rönnstrand L
    Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal and oncogenic forms of the receptor tyrosine kinase kit.
    Lennartsson J; Jelacic T; Linnekin D; Shivakrupa R
    Stem Cells; 2005; 23(1):16-43. PubMed ID: 15625120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.
    Tsujimura T; Kanakura Y; Kitamura Y
    Leukemia; 1997 Apr; 11 Suppl 3():396-8. PubMed ID: 9209403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
    Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
    Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.
    Wardelmann E; Neidt I; Bierhoff E; Speidel N; Manegold C; Fischer HP; Pfeifer U; Pietsch T
    Mod Pathol; 2002 Feb; 15(2):125-36. PubMed ID: 11850541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal transduction by several KIT juxtamembrane domain mutations.
    Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
    Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
    Yuzawa S; Opatowsky Y; Zhang Z; Mandiyan V; Lax I; Schlessinger J
    Cell; 2007 Jul; 130(2):323-34. PubMed ID: 17662946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms.
    Ma Y; Longley BJ; Wang X; Blount JL; Langley K; Caughey GH
    J Invest Dermatol; 1999 Feb; 112(2):165-70. PubMed ID: 9989791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.